Abstract
1/2014
vol. 6
Original paper
High-dose-rate interstitial brachytherapy for mobile tongue cancer: preliminary results of a dose reduction trial
J Contemp Brachytherapy 2014; 6, 1: 10–14
Online publish date: 2014/02/19
Purpose: To compare the outcome of our facility with another about the shortened schedule (60 Gy in 10 fractions to 54 Gy in 9 fractions) of high-dose-rate interstitial brachytherapy (HDR ISBT) for mobile tongue cancer.
Material and methods: Eighteen patients were treated with HDR ISBT as a monotherapy in dose reduction schedule with some unique technique to determine the border of tumor accuracy (lugol’s staining and metal marker), and to minimize adverse effect (lead-lined silicon block) at our facility.
Results: The 2-year local and regional control rates and cause-specific survival rate were 82%, 80%, and 83% and moderate to severe late complications occurred in five patients (28%), which were almost the same treatment results achieved by another facility.
Conclusions: We recommend 54 Gy in 9 fractions over 7 days as a feasible treatment to reduce patient discomfort in mobile tongue cancer patients.
Material and methods: Eighteen patients were treated with HDR ISBT as a monotherapy in dose reduction schedule with some unique technique to determine the border of tumor accuracy (lugol’s staining and metal marker), and to minimize adverse effect (lead-lined silicon block) at our facility.
Results: The 2-year local and regional control rates and cause-specific survival rate were 82%, 80%, and 83% and moderate to severe late complications occurred in five patients (28%), which were almost the same treatment results achieved by another facility.
Conclusions: We recommend 54 Gy in 9 fractions over 7 days as a feasible treatment to reduce patient discomfort in mobile tongue cancer patients.
Keywords
dose reduction, high-dose-rate brachytherapy, tongue cancer
Indexed in
Integrated with
Editorial Policies
